## Abstract Antibody to hepatitis B surface antigen (HBsAg) (anti‐HBs) can exist in patients with chronic hepatitis B virus (HBV) infection. To date, little is known about the association of concurrent HBsAg and anti‐HBs (concurrent HBsAg/ anti‐HBs) with hepatocellular carcinoma (HCC). The aim of t
Hepatitis B surface antigen in hepatic carcinoma
✍ Scribed by Janković, G.; Dojčinov, D.; Grbić, R.; Kovačević, N.; Adania, G.; Tomić, D.; Ješić, R.; Krstić, M.; Milinić, N.
- Book ID
- 123326756
- Publisher
- Elsevier Science
- Year
- 1990
- Tongue
- English
- Weight
- 95 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Hepatitis B virus (HBV) reinfection and recurrence of hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT) are associated with increased graft failure and reduced patient survival. We evaluated the effects of both HCC recurrence and HBV reinfection on the long-term survival of
Some individuals who are chronically infected with hepatitis B virus (HBV) eventually lose hepatitis B surface antigen (HBsAg). Hepatocellular carcinoma (HCC) has been demonstrated to occur in a few patients after loss of HBsAg. Neither factors associated with loss of HBsAg nor the incidence of HCC